Please assess the completion status of the following clinical trial:

Trial Title: Study of Combination Therapy With SYR-322

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject is an outpatient.~2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.~Exclusion Criteria:~1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.~2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYR-322 (Alogliptin) QD (Type: EXPERIMENTAL): SYR-322 25 mg, orally.
- Insulin (Type: PLACEBO_COMPARATOR): injection

Based on this trial design, predict the completion outcome and termination type (if applicable).